Open AccessAtria Score for Antithrombotic Agent Utilization in Ischemic Stroke Patients with Atrial Fibrillation
Author(s) -
Ivana Purnama Dewi,
Kristin Purnama Dewi,
Rizaldy Taslim Pinzon
Publication year - 2020
Publication title -
iop conference series. earth and environmental science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.179
H-Index - 26
eISSN - 1755-1307
pISSN - 1755-1315
DOI - 10.1088/1755-1315/441/1/012179
Subject(s) - medicine , antithrombotic , atrial fibrillation , stroke (engine) , comorbidity , anticoagulant , cardiology , rivaroxaban , warfarin , mechanical engineering , engineering
Antithrombotic therapy is recommended in atrial fibrillation (AF) management due to high risk of stroke. The assessment of stroke risk, as well as risk of bleeding, can help clinicians to make optimal management decisions. This study aimed to assess the stroke and bleeding risk using the ATRIA score and to compare the drug utilization pattern of antithrombotic therapy in post-ischemic stroke patients with AF comorbidity. This study is a single-center, retrospective observational study. From June 2009 to April 2019, we enrolled 165 post-ischemic stroke patients with AF comorbidity (mean age 68.24years; 47.3% female). One hundred nineteen patients were first stroke patients and 46 were recurrent stroke patients. Antiplatelets were predominantly prescribed (n=106, 64.2%). Out of 106 patients prescribed with antiplatelets, 39 (23,6%) patients had high a ATRIA Stroke Risk score, while as per ATRIA Bleeding Risk score, 66 (40%) patients had a low score. Conversely, an anticoagulant was rarely prescribed. A total of only 59 (35.7%) patients were prescribed with an anticoagulant, as single or combination. Out of 59 patients, an anticoagulant was commonly prescribed in high ATRIA Stroke Risk score patients (n=40, 24,3%). While as per ATRIA Bleeding Stroke score, an anticoagulant was commonly prescribed among low bleeding risk patients (n=47, 28.5%).